Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab ozogamicin in de novo AML
NCT04168502Phase 3Recruiting
- Sponsor
- GIMEMA
- Start
- Sep 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by GIMEMA. Started Sep 2020; status: recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04168502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168502.